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Abstract
Plasmodium falciparum malaria kills nearly a million people annually. Over 90% of these deaths occur in children under five
years of age in sub-Saharan Africa. A neutrophil mediated mechanism, the antibody dependent respiratory burst (ADRB),
was recently shown to correlate with protection from clinical malaria. Human neutrophils constitutively express Fc gamma
receptor-FccRIIA and FccRIIIB by which they interact with immunoglobulin (Ig) G (IgG)-subclass antibodies. Polymorphisms
in exon 4 of FCGR2A and exon 3 of FCGR3B genes encoding FccRIIA and FccRIIIB respectively have been described to alter
the affinities of both receptors for IgG. Here, associations between specific polymorphisms, encoding FccRIIA p.H166R and
FccRIIIB-NA1/NA2/SH variants with clinical malaria were investigated in a longitudinal malaria cohort study. FccRIIA-p.166H/
R was genotyped by gene specific polymerase chain reaction followed by allele specific restriction enzyme digestion.
FCGR3B-exon 3 was sequenced in 585 children, aged 1 to 12 years living in a malaria endemic region of Ghana. Multivariate
logistic regression analysis found no association between FccRIIA-166H/R polymorphism and clinical malaria. The A-allele of
FCGR3B-c.233C.A (rs5030738) was significantly associated with protection from clinical malaria under two out of three
genetic models (additive: p= 0.0061; recessive: p= 0.097; dominant: p= 0.0076) of inheritance. The FccRIIIB-SH allotype
(CTGAAA) containing the 233A-allele (in bold) was associated with protection from malaria (p= 0.049). The FccRIIIB-NA2*03
allotype (CTGCGA), a variant of the classical FccRIIIB-NA2 (CTGCAA) was associated with susceptibility to clinical malaria
(p= 0.0092). The present study is the first to report an association between a variant of FccRIIIB-NA2 and susceptibility to
clinical malaria and provides justification for further functional characterization of variants of the classical FccRIIIB allotypes.
This would be crucial to the improvement of neutrophil mediated functional assays such as the ADRB assay aimed at
assessing the functionality of antibodies induced by candidate malaria vaccines.
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Introduction
Plasmodium falciparum malaria kills nearly a million people
annually and over 90% of deaths occur in children under five
years of age in sub-Saharan Africa [1]. Several sero-epidemiolog-
ical studies have associated P. falciparum antigen-specific cytophilic
immunoglobulin (Ig) G (particularly IgG1 and IgG3) with
protection from clinical malaria [2–4] suggesting a critical role
for immune effector cells in malaria immunity. Monocytes, upon
activation by IgG opsonized infected erythrocytes are thought to
release certain, as yet uncharacterized, factors that inhibit intra-
erythrocytic parasite growth [5,6]. This mechanism, termed
antibody dependent cellular inhibition (ADCI), has been widely
studied in in vitro systems but has so far not shown any significant
correlation with protection against clinical malaria. On the other
hand a correlation has been reported between neutrophil
mediated antibody dependent respiratory burst (ADRB) and
protection from clinical malaria in two Senegalese populations
which differ in malaria transmission intensity [7]. Human
neutrophils constitutively express two receptors, namely Fc gamma
receptor (FccR)- FccRIIA and FccRIIIB [8], which bind the Fc
domain of IgG. These receptors complement each other
functionally [9]. FccRIIA is a transmembrane protein while
FccRIIIB has no transmembrane domain and is anchored in the
plasma membrane through a C-terminus linked glycosylpho-
sphatidylinositol moiety [10,11]. In addition to neutrophils, most
cells of the immune system, including monocytes, macrophages,
eosinophils, basophils, Langerhans cells, platelets, placental
endothelial cells and some T cells subpopulations are known to
express FccRIIA while FccRIIIB is expressed exclusively on
neutrophils [12]. Crosslinking of FccRIIA on neutrophils induces
phagocytosis of IgG-opsonised particles [13] while FccRIIIB
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crosslinking leads to neutrophil degranulation and generation of
reactive oxygen species (ROS), which have been shown to alter
FccRIIA avidity and efficiency in an allele-specific manner [14].
ROS are known to be highly toxic to intra-erythrocytic malaria
parasites [5,15,16] and high ROS production by neutrophils has
been correlated with fast P. falciparum clearance in Gabonese
children [17] and protection from clinical malaria in two
Senegalese populations [7].
Single nucleotide polymorphisms (SNPs) which alter the affinities of
both FccRIIA and FccRIIIB in binding IgG subclasses have been
described. In the present study, we hypothesised that the implications
of these polymorphisms in the described neutrophil mediated immune
correlate of clinical protection from malaria (the ADRB mechanism)
by Joos and colleagues [7], could be critical to the outcome of P.
falciparum infection. In the FCGR2A gene (NM_021642.3), a non-
synonymous variant, c.497G.A (rs1801274) in exon 4, which
specifies the ligand binding domain of the receptor, causes an arginine
(R) substitution of an histidine (H) amino acid at position 166 of the
polypeptide (p.H166R) [18]. The FccRIIA-H166 allele has higher
affinity for human IgG2 and IgG3, compared to FccRIIA-R166
which binds weakly [19]. In a recent study, Schuldt and colleagues
found FccRIIA-R166/R166 homozygosity to be associated with
severe malarial anaemia in Ghanaian children [20]. FccRIIIB bears
the neutrophil antigen (NA) polymorphism in its membrane-distal Ig-
like domain and is found in three polymorphic forms, called human
neutrophil antigen (HNA)-1a (or NA1), HNA-1b (or NA2) and HNA-
1c (or SH), which are encoded by FCGR3B*1, FCGR3B*2 and
FCGR3B*3 alleles, respectively [21]. The FCGR3B*1 and FCGR3B*2
alleles differ in five nucleotide positions; c.108C.G; c.114T.C;
c.194A.G; c.244A.Gand c.316A.G [22] in exon 3 of the FCGR3B
gene (NM_00570.4) which results in four amino acid changes at
positions; p.S36R; p.N65S; p.N82D and p.I106V of the peptide chain
with the c.114T.C being a synonymous coding SNP [23]. FccRIIIB-
NA1 facilitates phagocytosis of IgG1- and IgG3-opsonized particles
more efficiently than FccRIIIB-NA2. This may be due to the presence
of two additional N-linked glycosylation sites in FccRIIIB-NA2
compared to FccRIIIB-NA1 [24]. The nucleotide sequence of the
FccRIIIB coding region of FCGR3B*3 is identical to the FCGR3B*2
sequence except for a SNP c.233C.A (rs5030738) encoding p.A78D
resulting in the expression of the FccRIIIB-SH allo-antigen [25]. This
allotype has been associated with about a third of FccRIIIB alleles and
higher expression levels of FccRIIIB but its influence on receptor
function is unclear [26]. Furthermore, in individuals whose neutro-
phils lack the FccRIIIB molecule (NAnull) the corresponding gene
deletion has been described [27]. Sequencing analysis has identified
variants of the classical FccRIIIB-NA1/NA2 allotypes but their
functional significance have, as yet, not been characterised [28–30].
The FccRIIIB-NA2 allotype in combination with the FccRIIA-166H
allele have been associated with cerebral malaria in Thai individuals
[31] and severe malarial anaemia in Kenyan children [32]. In general,
malaria immunogenetic studies have so far mainly focused on severe
forms of malaria using either cross-sectional and/or case-control study
data [20,32–34]. In the present study, we successfully elucidated
associations between FCGR3B and FCGR2A polymorphisms and
clinical malaria using data from a well characterised longitudinal
cohort study.
Results
Demographic and clinical characteristics of study
population
Of the 669 out of 798 children who successfully completed the
42 week longitudinal follow up, DNA was available for 585
(87.4%). These children were distributed across six villages as
follows: Asutsuare (ASU) (169), Kewum (KEW) (138), Avakpo
(AVA) (33), Mafikorpe (MAF) (36), Osuwem (OSU) (71) and
Volivo (VOL) (138) (Table 1). A total of 329 (56.2%) children were
#5 years of age and 88 (15.0%) were sickle cell positive. The study
population consisted predominantly of the Ga-Adangbe (n= 430,
73.5%) and Ewe (n= 76, 13.0%) ethnic groups. The remaining
(n = 79, 13.5%), children belonged to the Akan, Hausa or Fulani
ethnic groups. Children who used bed net constituted 42.1% of the
study population. The gender distribution was not significantly
different between the villages (p=0.75, x2 analysis) while the
distribution of age, blood group, ethnicity and sickle cell status
were significantly different between the villages (p#0.0007, x2
analysis) (Table 1).
P. falciparum infections in the study cohort
The incidence of clinical malaria during the follow up period
was low (52 cases, 8.9%). These individuals were considered
susceptible to clinical malaria while those who never had clinical
malaria were considered protected. The protected group was sub-
categorized into two: (1) any individual with no malaria episode
and (2) only individuals with no malaria episodes but with parasites
detectable by microscopy at any time point during the follow up
period. The overall number of susceptible and protected
Table 1. Demographics and clinical characteristics of study
participants.
ASU KEW AVA MAF OSU VOL p-value¥
N 169 138 33 36 71 138
Age group (years)
1–5 122 66 17 15 50 59
6–12 47 72 16 21 21 79 ,0.0001
Sex
Male 83 71 19 17 32 62
Female 86 67 14 19 39 76 0.75
Sickle cell
Negative 152 129 12 23 68 113
Positive 17 9 21 13 3 25 ,0.0001
Blood group
O 96 64 10 11 37 62
A 33 31 14 7 8 18
B 32 36 9 13 19 46
AB 8 7 0 5 7 12 0.0007
Bed net use
Yes 63 65 21 26 26 45
No 106 73 12 10 45 93 ,0.0001
Ethnic group
Ga-Adangbe 124 103 15 14 67 107
Ewe 15 7 14 18 1 21
Other 30 28 4 4 3 10 ,0.0001
Clinical malaria
status
Susceptible 12 15 2 0 9 14
Protected 157 123 31 36 62 124 0.24
¥p-values refer to chi-square tests. ASU: Asutsuare; KEW: Kewum-Atrobinya;
AVA: Avakpo; MAF: Mafikorpe; OSU: Osuwem; VOL: Volivo.
doi:10.1371/journal.pone.0046197.t001
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individuals did not differ significantly (p=0.24, x2 analysis) among
the six villages (Table 1). Logistic regression analyses investigating
the association of the covariates, age groups, sex, blood group,
ethnicity and sickle cell status with clinical malaria, found an
association with ethnicity. Individuals of the Ewe ethnic group had
a significantly reduced risk of clinical malaria compared to other
ethnic groups (likelihood ratio test: p(LR test) = 0.013) (Table 2).
Distribution of FCGR2A and FCGR 3B genotype in
Ghanaian children
The FccRIIA-p.H166R (c.497A.G) genotypes were deter-
mined by gene specific polymerase chain reaction amplification
followed by allele specific restriction enzyme digestion (PCR-
ASRED). The minor allele frequency (which is this population was
the A-allele) was 41.0% and there was no deviation from HWE
(p=0.690, x2 analysis). Nucleotide sequencing of exon 3 of
FCGR3B identified the six polymorphisms (c.108C.G,
c.114T.C, c.194A.G, c.233C.A, c.244A.G and c.316A.G),
defining the FccRIIIB-NA1/NA2/SH allotypes. The previously
described c.197T.G, and c.297G.T polymorphisms were also
found in 87 (14.9%) and 46 (7.9%) individuals respectively. A new
SNP, c.232G.A was identified in five (0.85%) of the study
participants. All the SNPs were in HWE, p.0.05 (Table 3). The
distribution of the genotypes was not significantly different
between the ethnic groups except for the FCGR2A-c.497A.G
(p=0.038, x2 test) and FCGR3B-c.194A.G (p=0.017, x2 test)
SNPs (Table S1).
FCGR2A and FCGR 3B genotypes and clinical malaria
The distribution of the FCGR2A-c.497A.G (FccRIIA-
p.H166R) genotype frequencies among the susceptible and
protected groups did not differ significantly in a multivariate
analysis and had no influence on the outcome of P. falciparum
infection (p(LR test) = 0.80) (Table S2). The FCGR3B-c.233C.A
(FccRIIIB-p.A78D) polymorphism showed a statistically signifi-
cant association with the outcome of P. falciparum infection (p(LR
test) = 0.009) (Table S1). The A-allele was significantly associated
with protection from clinical malaria under two out of the three
genetic models of inheritance (additive: p=0.0061, recessive:
p=0.097 and dominant: p=0.0076) analysed using a control
group that included all individuals with no clinical malaria during
follow up (Table 4). The confounding effect of possible heteroge-
neity in exposure was investigated by repeating the analysis with a
redefined control group comprising only individuals with no
malaria episodes but with a definitive evidence of exposure ie. with
parasites detected by microscopy during follow up. The same
marker (c.233A-allele) was significantly associated with protection
from malaria (Table S3) under the same genetic models of
inheritance previously observed, confirming the initial observation.
Disease association analyses for FCGR3B were restricted to the six
SNPs encoding the FccRIIIB-NA1/NA2/SH allotypes. Of the
three additional SNPs, only the T-allele of c.297G.T was
significantly associated with protection from clinical malaria
(OR=0.307, 95%CI= 0.16–0.61, p=0.0016, Fisher’s exact test).
Table 2. Covariates association with clinical malaria.
Covariates Susceptible (n=52) Protected (n =533) OR(95%CI)a p-valuea LR test p-value
Age group (years)
1–5 29 300 1
6–12 23 233 1.01 (0.56–1.81) 0.97 0.97
Sex
Male 25 259 1
Female 27 274 0.96 (0.54–1.72) 0.89 0.89
Sickle cell
Negative 45 452 1
Positive 7 81 0.94 (0.37–2.07) 0.89 0.89
Blood group
O 26 254 1
A 6 105 0.59 (0.22–1.42) 0.27
B 15 140 1.08 (0.54–2.11) 0.81
AB 5 34 1.58 (0.50–4.16) 0.39 0.46
Bed net use
Yes 20 226 1
No 32 307 1.06 (0.58–1.96) 0.85 0.85
Ethnic group
Other 8 71 1
Ga-Adangbe 43 387 0.97 (0.46–2.33) 0.95
Ewe 1 75 0.12 (0.01–0.67) 0.047 0.013
Odds Ratios (OR) and 95% confidence intervals (CI) were determined using multivariate logistic regression.
aAnalysis for each covariate was adjusted by the other remaining covariates: age groups, sex, sickle cell status, blood group, bed net use and ethnic group. The
likelihood ratio (LR) test result compares the adjusted model to a model which only includes the adjusting factors and thereby tests if the variable has an effect on
susceptibility.
doi:10.1371/journal.pone.0046197.t002
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FCGR3B haplotype association with clinical malaria
The six SNPs defining the FccRIIIB-NA1/NA2/SH were
investigated for association with clinical malaria. Pairwise r2 values
between these SNPs (0.08#r2#0.86) from linkage analysis
revealed a significant linkage between most of the SNPs
(Figure 1A). A haplotype block was defined to include all SNPs
in order to estimate the frequencies of FccRIIIB allotypes in the
entire study population (Figure 1A). The haplotype analysis
identified the three major FccRIIIB allotypes (FccRIIIB-NA1/
NA2/SH), two variants of FccRIIIB-NA1 (FccRIIIB-NA1*02 and
FccRIIIB-NA1*06) and two variants of FccRIIIB-NA2 (FccRIIIB-
NA2*02 and FccRIIIB-NA2*03) (Figure 1B). The FccRIIIB-
NA2*03 was significantly associated with susceptibility to clinical
malaria (OR=2.67, 95%CI= 1.27–5.59, p=0.0092) while the
FccRIIIB-SH allotype showed a borderline significant association
with protection (OR=0.42, 95%CI=0.18–1.00, p=0.049)
(Figure 1B). When only individuals who did not have malaria
but with detectable parasites during the follow up period were
considered as controls in the haplotype association analysis, logistic
regression could not be performed because the risk haplotype
FccRIIIB-NA2*03 was completely absent in the control group
(n = 57).
Population differences of FCGR3B-c.233C.A
polymorphism
Exon 3 of FCGR3B was sequenced in 132 native Danish blood
donors and genotype distributions compared to the Ghanaian
population to investigate differences and possible selection.
Sequence analysis found all the six SNPs defining the FccRIIIB-
NA1/NA2/SH system. All SNPs were in HWE (p.0.05). One
person carried synonymous variant (c.201C.T). The c.233C.A
genotype frequencies were significantly different (p,0.0001, x2
analysis) between the Ghanaian and Danish populations (Figure 2).
Although the A-allele remained the minor allele in both
populations, none of the 132 Danes was homozygous compared
to the 8.5% homozygosity in the Ghanaian population. Only 10
individuals were heterozygous in the Danish population. The
Tajima’s D statistic estimated for FCGR3B exon 3 showed a
significant positive deviation from the values expected under
neutrality in both the Ghanaian (D= 2.9, p,0.05) and Danish
(D=2.2, p,0.05) populations. Comparisons with data from the
1000 Genomes Project database showed that the A-allele
frequency for the African (AFR) (17.9%) super population was
similar to that in the Ghanaians (21.4%) in this study. Similarly,
the A-allele frequency for the Ad Mixed American (AMR) (3.3%)
and European (EUR) (0.8%) super populations were comparable
to the Danes (3.8) (Table 5). Thus, the A-allele, which was
associated with protection from P. falciparum malaria, was more
frequent in malaria endemic populations than in non-endemic
populations. To further evaluate the extent of divergence with
respect to this polymorphism, pairwise FST indices were calculated
for all five populations (Ghanaians, Danes, AFR, AMR and EUR).
The AFR and the Ghanaian population shared a pairwise FST
value of 0.004 while all comparisons between the malaria endemic
(Ghanaians and AFR) and the malaria non-endemic (Danes, AMR
Table 3. FCGR3B allele frequencies and Hardy-Weinberg (HW) estimations in protected individuals.
Variation ID Alleles* Amino acid change* Minor allele (Frequency) HW p-valuea
rs403016 c.108C.G p.S36R G (0.491) 1.00
rs447536 c.114T.C Synonymous coding C (0.471) 0.62
rs448740 c.194A.G p.N65S A (0.390) 0.61
rs5030738 c.233C.A p.A78D A (0.214) 0.49
rs428888 c.244A.G p.N82D A (0.491) 0.066
rs2290834 c.316A.G p.I106V G (0.251) 0.29
*Allele and amino acid numberings refer to positions in FCGR3B transcript ENST00000367964.
aHW estimations based on children (n = 267) who had diploid copies of FCGR3B, were the first sibling in a family and were not susceptible to clinical malaria in the
observation period.
doi:10.1371/journal.pone.0046197.t003
Table 4. Single marker association of FCGR3B alleles with clinical malaria.
MAF Additive model Recessive model Dominant model
SNP ID Minor Allele Protected Susceptible OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
rs403016 C 0.49 0.50 1.04 (0.71–1.54) 0.84 1.38 (0.74–2.53) 0.31 0.82 (0.44–1.53) 0.53
rs447536 C 0.47 0.46 0.98 (0.67–1.45) 0.94 1.11 (0.57–2.13) 0.77 0.88 (0.47–1.63) 0.68
rs448740 A 0.40 0.38 0.95 (0.64–1.42) 0.82 1.16 (0.56–2.40) 0.69 0.80 (0.45–1.44) 0.46
rs5030738 A 0.22 0.10 0.43 (0.23–0.78) 0.0061 0.18 (0.02–1.36) 0.097 0.37 (0.18–0.77) 0.0076
rs428888 A 0.50 0.40 0.74 (0.51–1.06) 0.10 0.52 (0.25–1.07) 0.075 0.74 (0.40–1.36) 0.34
rs2290834 G 0.27 0.22 0.81 (0.52–1.27) 0.36 0.87 (0.34–2.20) 0.77 0.69 (0.37–1.27) 0.23
Odds ratio (OR) and 95% confidence intervals (CI) were determined using multivariate logistic regression controlling for age, gender, ethnicity, sickle-cell status, FCGR3B
copy number, blood group, family structure and use of bed net. MAF: minor allele frequency.
All individuals who never had malaria despite parasitaemia at any time point (monthly blood slide) during the study, plus all individuals who never had malaria but
without detectable parasitaemia by microscopy.
doi:10.1371/journal.pone.0046197.t004
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and EUR) populations yielded consistently higher FST values
(0.098#FST#0.194) (Table 6).
Discussion
Using PCR-ASRED and exon 3 nucleotide sequencing data for
FCGR2A and FCGR3B respectively, the association between SNPs
which alter the affinity of these receptors for IgG subclasses and
clinical malaria were studied in a cohort of Ghanaian children.
There was no association between the FCGR2A-c.497A.G
(FccRIIA-p.H166R) polymorphism and clinical malaria while
the A-allele of FCGR3B-c.233C.A polymorphism (rs5030738)
was strongly associated with protection from clinical malaria.
Haplotype analysis identified the FccRIIIB-SH allotype
(CTGAAA) containing the c.233A-allele (in bold) to be associated
with protection while a variant of FccRIIIB-NA2, the FccRIIIB-
NA2*03 allotype (CTGCGA) was associated with susceptibility to
clinical malaria. Individuals of the Ewe ethnic group showed a
Figure 1. Studied SNPs in the FCGR3B gene, linkage disequilibrium (LD) patterns and haplotype association analysis. A) A schematic
of exon 3 FCGR3B gene (NM_000570.4) and LD plot of the respective SNPs visualised using Haploview v4.2. The LD plot shows pairwise r2 values
(6100) given in the squares for each comparison between the SNPs. White squares represent r2 values equal to 0. Different shades of grey represent
r2 values between 0 and 1. B) Haplotype associations with susceptibility to clinical malaria compared to clinically protected individuals. Odds ratio
(OR) and 95% confidence intervals (CI) were determined using multivariate logistic regression controlling for age, gender, ethnicity, sickle-cell status,
FCGR3B copy number, blood group and use of bed net. The haplotype with the highest frequency in the study population was considered the
reference group in the multivariate logistic regression analyses. Variant first reported in this study, the associated gene for NA1*06 is
FCGR3B*01A194G, G316A; Y Variants first reported by Matsuo et al, [28], the associated genes for NA1*02, NA2*02 and NA2*03 are FCGR3B*01G316A,
FCGR3B*02G194A and FCGR3B*02A244G respectively.
doi:10.1371/journal.pone.0046197.g001
Figure 2. FCGR3B-c.233C.A genotypes. Genotype distribution
compared between malaria endemic (Ghanaian) and malaria non
endemic (Danish) populations.
doi:10.1371/journal.pone.0046197.g002
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reduced risk to clinical malaria compared to other ethnic groups,
however, the distribution of genotypes was not different between
the ethnic groups except for FCGR2A-497A.G and FCGR3B-
194A.G. These genotypes had no association with clinical
malaria. Also, while the ethnic group distribution was different
between the villages, the number of susceptible and protected
individuals was not different between the villages. Thus, the
genetic associations with protection and susceptibility observed
here could not be due to a bias caused by ethnicity. Heterogeneity
in malaria exposure is an important confounder in association
studies [35]. In the current study, the outcome of the association
analysis did not differ whether or not the control group included
individuals with no malaria and no detectable asymptomatic
parasitaemia by microscopy. This suggests exposure may have
been homogeneous and that asymptomatic malaria infection in
some of the individuals went undetected due to immunity resulting
in sub-microscopic parasitaemia [35]. The protective allele
(c.233A), though a minor allele in all populations in this study,
still had a significantly higher frequency in malaria endemic
populations compared to the non-endemic populations, possibly
because of positive selection by P. falciparum malaria. The Tajima’s
D estimates show that FCGR3B exon 3 is under strong selection
pressure in the Ghanaian populations and also to a lesser extent in
the Danish population.
Both sero-epidemiological [2–4] and in vitro studies [5,36] have
demonstrated that cytophilic IgG (1 and 3) subclasses are the most
important in controlling parasites multiplication and/or disease,
emphasizing the importance of effector cells such as monocytes
and neutrophils in malaria immunity. Neutrophils are the most
abundant leucocytes and known to have both high phagocytic and
cytotoxic capabilities through the generation and release of potent
cytotoxic mediators such as reactive oxygen species (ROS) and
proteases [37]. They are the main effector cells in the ADRB
mechanism recently shown to correlate with protection from
clinical malaria [7]. Neutrophils engage IgG1 and IgG3 immune
complexes (ICs) through FccRIIA and FccRIIIB constitutively
expressed on the cell surface. Although these receptors function
synergistically, it has been shown that phagocytosis by neutrophils
is primarily dependent on FccRIIA crosslinking [13] while ROS
release is by FccRIIIB crosslinking with ICs [14]. The lack of
association between clinical malaria and any of the genotypes of
FccRIIA-p.H166R in this study suggests that, neutrophil ROS
activity may be paramount to phagocytic activity in protecting
against clinical malaria since only FccRIIIB polymorphisms could
explain the outcome of P. falciparum infection. This notion is
supported by both in vitro studies of ROS toxicity on intra-
erythrocytic malaria parasites [5,15,16] and field studies where
high ROS production by neutrophils correlated with fast P.
falciparum clearance [17] and protection from clinical malaria [7].
The c.233A-allele of FCGR3B which was associated with
protection from clinical malaria in the present study causes a
replacement of the hydrophobic amino acid alanine (A) with the
negatively charged aspartic acid (D) at position 78 in the NA2
protein. This substitution results in the SH allotype which also
showed association with protection. The functional implications of
this p.A78D substitution in receptor-ligand (antibody) interactions
have not been conclusively shown. Koene and colleagues [26]
suggest it may influence a ligand epitope possibly located in the
membrane distal Ig-like domain. In the same study, the SH
allotype was associated with high expression levels of FccRIIIB.
Thus, protection from clinical malaria seen in individuals with the
A-allele and SH allotype may be due to increased ROS production
as a result of both enhanced antibody-receptor interaction and
increased FccRIIIB density on neutrophil cell surface. The
maximum statistical power for A-allele association with protection
was observed under the dominant model with homozygous
individuals having over 60% reduced risk to acquiring clinical
malaria compared to the other models tested. In genetic
association studies, maximum power to detect significant associ-
ation is reached when the ‘true’ mode of inheritance and the
genetic model used in the analysis are concordant [38]. Thus, the
dominant model best explains the mode of inheritance of the
c.233C.A polymorphism in the Ghanaian cohort studied.
Association studies based on Polymerase Chain Reaction-
Sequence Specific Primer (PCR-SSP) data of FCGR2A and
FCGR3B have found individuals carrying the NA2 allotype in
combination with FccRIIA-166H have an increased risk of
developing cerebral malaria [31] and severe malarial anaemia
[32]. Here, using FCGR3B-exon 3 nucleotide sequencing data, we
find a previously reported variant of FccRIIIB-NA2, FccRIIIB-
NA2*03 (associated gene: FCGR3B*02A244G, [28]) to be associ-
ated with susceptibility to clinical malaria. While the PCR-SSP
technique [39] is an established method for genotyping FCGR3B
and has been extensively used, sequencing data [28–30,40] have
consistently shown that the FCGR3B gene is more polymorphic
Table 5. rs5030738 (c.233C.A) allele distribution among malaria endemic and malaria non-endemic populations.
Malaria endemic Malaria non-endemic
rs5030738 c.233C.A Ghanaians (n =585) AFR* (n=248) Danes (n =132) EUR* (n=381) AMR* (n =181)
A-allele % 21.4 17.9 3.8 0.8 3.3
C-allele % 78.6 82.1 96.2 99.2 96.7
*Allele frequency data from the 1000 Genomes project data base. AFR: African; AMR: Ad Mixed American; EUR: European.
doi:10.1371/journal.pone.0046197.t005
Table 6. Pairwise genetic distances between malaria versus
non-malaria population with respect to c.233C.A (rs5030738)
polymorphism.
Population AFR Danes EUR AMR
Ghanaian 0.004 0.131 0.194 0.141
AFR 0.098 0.159 0.106
Danes 0.020 0.000
EUR 0.015
FST distance (Latter et al., 1972).
Allele frequency data from the 1000 Genomes Project database (http://
browser.1000genomes.org/Homo_sapiens/Variation/
Population?db= core;g = ENSG00000162747;r = 1:161592986-
161601753;t = ENST00000531221;v = rs5030738;vdb = variation;vf = 8673417).
AFR: African; AMR: Ad Mixed American; EUR: European.
doi:10.1371/journal.pone.0046197.t006
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than was previously thought. Variations at the allotype defining
sites could result in aberrant PCR-SSP typing [30,40]. More
importantly, the PCR-SSP method cannot differentiate between
the classical NA2 and the variant NA2*03 and will simply type
both as NA2. Thus, the PCR-SSP method alone may not be
enough to sufficiently characterise FccRIIIB allotypes in disease
association studies. It is not clear how exon 3 sequencing data
would have affected the conclusions from PCR-SSP typing
association studies particularly where NA2 was associated with
disease outcome. The risk associated allotype NA2*03 found in the
Ghanaian population, differs from the classical NA2 by an
asparagine (N) to aspartic acid (D) substitution at position 82 of the
FccRIIIB protein. This N82D substitution results in a loss of one
potential N-glycosylation site of NA2. It is conceivable, that the
NA2*03 variant would have one-less (ie. 5) potential N-glycosyl-
ation sites. NA2 shows a reduced capacity to facilitate phagocy-
tosis, respiratory burst and degranulation responses compared to
NA1, a property attributed to the extensive glycosylation in NA2
than in NA1 [9,41]. Thus, it would be expected that the NA2*03
variant possessing one-less glycosylation site compared to NA2
should have a higher affinity for IgG1 and IgG3 than NA2 and
hence be the more efficient receptor. However, no study has as yet
investigated the binding affinity of the NA2*03 variant for IgG1
and IgG3 or the possible conformational changes due to the
replacement of a potential glycosylated group (p.82N) with an
unglycosylated charged group (p.82D). N-glycosylation is a
common feature of many membrane-bound and extracellular
proteins in animals and the carbohydrate groups are considered
crucial for biological functions such as proper protein folding [42],
protein stability and solubility [43], ligand binding affinity [44],
signal transduction [45], and immunogenicity [46]. Thus, it is
plausible that the p.N82D substitution in the NA2*03 variant may
alter an important biological mechanism critical for neutrophil
respiratory burst and hence predispose to clinical malaria. Further
studies are needed to delineate the possible functional conse-
quences of the NA2*03 polymorphism in FccRIIIB.
The Tajima’s D analysis showed exon 3 of FCGR3B to be under
selection pressure in both the Ghanaian and the Danish
populations; however, it is not clear what may be driving the
selection in these different populations. Malaria has been
considered the strongest known selective pressure in the recent
history of the human genome [47]. There was a higher frequency
of the c.233A allele in malaria endemic populations and high
pairwise FST indices (0.098#FST#0.194) between the malaria
versus non-malaria endemic populations. These observations
support the notion that malaria may be a significant contributor
to the selection pressure, at least in the Ghanaian and African
(AFR) populations. However, other possible factors that could
explain the selection in both the malaria and non-malaria endemic
populations may include inflammatory diseases such as rheuma-
toid arthritis [48] or periodontal diseases (PD). PD is a widespread
condition and several studies have associated FccRIIIB polymor-
phisms with PD in different populations [49]. In animal studies,
PD has been shown to contribute to perinatal mortality [50]. A
recent study in humans concluded that, in cases of extreme
prematurity, maternal PD may be a significant contributor to
perinatal mortality [51]. Given the contribution of PD in perinatal
mortality and the association of FccRIIIB polymorphisms in the
pathogenesis of PD, we speculate that PD may contribute to the
selection pressure acting on exon 3 of FCGR3B. It is however,
worth noting that the present data does not clearly show which
modes of natural selection may be at play in these two populations.
Further studies are needed to clearly define the forces of selection
on FCGR3B-exon 3 in these populations.
In conclusion, the present study has identified the c.233A allele
of FCGR3B-c.233C.A (rs5030738) and the FccRIIIB-SH
(CTGAAA) haplotype to be associated with protection from
clinical malaria. The FccRIIIB-NA2*03 (CTGCGA) variant of
FccRIIIB-NA2 (CTGCAA) was associated with susceptibility to
clinical malaria in the Ghanaian population. The study provides
the justification for a more detailed functional characterisation of
the FccRIIIB-SH and FccRIIIB-NA2*03 haplotypes in relation to
neutrophil functionality especially in respiratory burst activity.
Materials and Methods
Ethics Statement
Ethical approval for the study was given by the Institutional
Review Board of the Noguchi Memorial Institute for Medical
Research (NMIMR) of the University of Ghana, Accra, Ghana.
Written informed consent was given by the parents and guardians
of children before they were enrolled into the study. Ethical
approval for Danish blood donor samples was given by the
Scientific Ethics Committee of Copenhagen and Frederiksberg,
Denmark. DNA samples from a total of 132 anonymous Danish
blood, obtained for control purposes from Copenhagen University
Hospital, were analysed in order to allow population comparisons
of genotype distributions. These individuals are resident of central
Copenhagen and provided written consent to have a small portion
of their blood stored, anonymously, and used for research
purposes. Blood donors in Denmark must be between the ages
of 18 and 60. All data were analysed anonymously.
Study area, population and baseline sampling
The study was conducted in Asutsuare (ASU) (about 120 km
north-east of Accra) and five neighbouring villages: Kewum-
Atrobinya (KEW), Avakpo (AVA), Mafikorpe (MAF), Osuwem
(OSU) and Volivo (VOL) of the Damgbe West District of the
Greater-Accra Region of Ghana. The villages are only about 2-
5 km apart. Like many other parts of Ghana, the climate of the
area is characterised by two major seasons: a dry or the harmattan
season (December to March) and a wet or the rainy season (June to
August), however, there are also some few rains in November and
early December, just before the onset of the harmattan season.
Malaria transmission occurs throughout the year but peaks during
and after the rains (September and January). P. falciparum
constitutes 98% of all infection with the remaining 2% due to P.
malariae and P. ovale [52]. The population is predominantly of the
Ga-Adangbe ethnic origin but is interspersed with other ethnic
groups such as the Ewes and the Akans. There are two health
centres serving all these communities: Osudoku Community
Health Centre at Asutsuare and the Osuwem Community Health
Centre. In addition, the Akuse Hospital, about 10 km away serves
as a referral hospital for cases beyond the capacity of the
community health centres.
Altogether, 798 children (aged 1 to 12 years old) were enrolled
and were followed up actively and passively for malaria case
detection in a 42 week longitudinal cohort study. Genomic DNA
for analysis was available for 585 of the 669 children who
successfully completed the follow up without missing at most three
successive weekly visits. Of these 585 children, there were 316
singletons, 91 families with two children enrolled, 17 families with
3 children enrolled and 9 families with 4 children enrolled.. At
baseline (enrolment), 5 ml EDTA-anticoagulated venous blood
and thick and thin film blood slides were obtained from all
individuals prior to the malaria transmission season (May 2008) for
baseline immunological and parasitological determinations. Blood
group and sickle cell status of each individual were determined by
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a commercial blood grouping kit (Biotec Laboratories Limited,
UK) and the sodium metabisulphite test respectively and
haemoglobin (Hb) level was measured using the Hemocue-Hb
201 (Angelhom, Sweden). Blood was centrifuged to separate
plasma and peripheral blood mononuclear cells (PBMCs) and
stored at 280uC and in liquid nitrogen respectively. The thick and
thin blood film slides were stained with Giemsa and examined for
baseline asymptomatic parasitaemia. A slide was negative if no
parasite was visualised in 200 oil fields of a thick film. For slides
that were positive, parasites were counted per 200 white blood
cells (WBCs) and parasite densities calculated by assuming 8,000
WBCs/ml blood. A standardised questionnaire was used to obtain
epidemiological, anthropometrical and clinical data of all study
participants during the enrolment.
Danish Donors
DNA samples from a total of 132 anonymous Danish blood
donors, obtained for control purposes, were analysed in order to
allow population comparisons of genotype distributions. These
individuals are resident of central Copenhagen and provided
consent to have a small portion of their blood stored,
anonymously, and used for research purposes. Blood donors in
Denmark must be between the ages of 18 and 60 [33].
Parasitological and Clinical Surveillance
Parasitological surveillance for malaria infection was carried out
monthly for each study participant during the follow-up period.
This involved obtaining thick and thin blood film slides from finger
pricks by trained medical personnel. In addition, about 500 ml of
blood was collected during the monthly finger pricking to obtain
plasma for immunological analyses. The remaining packed cells
were stored at 280uC for DNA purification for genetic analyses.
The active case detection surveillance comprised weekly visits to
each participant’s home, where a morbidity questionnaire
(investigating symptoms occurring in the preceding week) was
administered by trained Field Assistants. The presence or absence
of fever (measured axillary temperature of $37.5uC, or reported)
was ascertained. Study participants complaining of symptoms
suggestive of malaria were referred for treatment at the respective
health centres. In the passive case detection surveillance, visits by
participants to the health centres without prior referral from a field
assistant were documented. In both the active and passive case
detection, Hb level was measured and thick and thin blood films
were obtained from study participants with febrile temperature
(.37.5uC) or reported febrile temperature prior to treatment.
Clinical malaria was defined as slide positive for any asexual P.
falciparum parasitaemia with at least one other sign of malaria such
as vomiting, diarrhoea, or malaise. Malaria was treated with
artesunate-amodiaquine combined dose therapy which was the
recommended standard treatment for malaria in Ghana. At the
end of the study, on the basis of the clinical and parasitological
data obtained, the study population was divided into three groups:
(1) those susceptible, in which parasitaemia was associated with
febrile disease, and (2) those apparently protected against clinical
manifestation despite parasitaemia and (3) those apparently
protected against clinical manifestation without detectable para-
sitaemia by microscopy.
FCGR2A genotyping
Genomic DNA was purified from packed cell samples using the
MaxwellH16 system (Promega, Madison, USA) following manu-
facturer’s guidelines. Genotyping of FccRIIA-p.H166R was done
by the gene specific polymerase chain reaction (PCR) amplifica-
tion followed by allele specific restriction enzyme digestion
(ASRED) method [53]. The final BstUI restriction digestion
products were visualized as 343 bp (H allele) and 322 bp (R allele)
bands on 3% agarose (SeaKemHGTGH Agarose, ME) with
ethidium bromide (AppliChem, Damstadt, Germany) staining.
Both fragments were present for heterozygous individuals.
FCGR3B sequencing
We designed a protocol to specifically amplify and sequence exon
3 of the FCGR3B gene from genomic DNA. First, an approximately
4.3-kb fragment of the FCGR3B gene using the sense primer (59-
CTCCATTGCGAGACTTCAGAT-39) placed in exon 1 and the
antisense primer (59-CGTGGTTTCTAAGGTGTCACAGG-39),
positioned within intron 3. A 30-cycle amplification process
consisting of denaturation at 95uC for 30 s, annealing at 63uC for
30 s and extension at 72uC for 5 mins was performed using
PfuUltraH high-fidelity DNA polymerase (Stratagene, USA). The
product was gel purified using E.Z.N.AH Gel Extraction Kit
(Omega Bio-Tek, Inc., GA) and used as template in a nested PCR to
amplify exon 3 of FCGR3B with the M13 tagged (in lower case)
sense (59-tgtaaaacgacggccagtGTCAGCTTCATGGTCTTG-
GATTG-39) and antisense (59-caggaaacagctatgaccACACATTCA-
CATTGTATGCACTCCA-39) primers. The 38 cycle amplifica-
tion consisted of denaturation at 94uC for 30 s, annealing at 58uC
for 30 s and extension at 72uC for 45 sec using TEMPase hotstart
DNA polymerase (Biomol, Germany). The nested PCR product was
then sequenced with M13 primers. The low affinity FCGR locus
contains regions of copy number variation (CNV) which can alter
receptor expression and leukocyte responses to IgG. However,
previous FCGR3B CNV data determined by the SALSAHmultiplex
ligation probe amplification (MLPAH) kit P110-B1/P111-B1 FCGR
(Lot 0210, 0409; v.08) (MRC Holland) on the same samples in the
present study found no association with and clinical malaria (Adu
et al., unpublished).
Statistical analysis
Demographic and clinical characteristics of the study popula-
tion were compared across village of residence (x2-test). Since the
risk of clinical malaria is known to be high in children aged 5 years
and below, age was modelled as a categorical variable with two
levels (1–5 years, and 6–12 years). Logistic regression analyses and
likelihood ratio tests were carried out to evaluate the association of
the variables, age group, sex, sickle cell status, blood group, use of
bed net and ethnic group with clinical malaria. The genotype
distribution of the SNPs was compared across ethnic groups (x2-
test). To test Hardy Weinberg equilibrium (HWE), we used the
data of n= 267 children who had diploid copies of FCGR3B, were
the first sibling in a family and were not susceptible to clinical
malaria in the observation period. The exact test (HWE.exact)
implemented in the R-package ‘genetics v.1.3.6’ (http://CRAN.R
project.org/package = genetics) was used. For each of the SNPs,
the minor allele (single marker) association with clinical malaria
was calculated under the three genetic models of inheritance
(additive, recessive and dominant) using logistic regression
adjusting for age group, sex, sickle cell status, blood group, use
of bed net and ethnic group. Two different control groups were
defined: (1) all individuals with no malaria episodes but with
definitive exposure as indicated by parasites detectable by
microscopy during the follow up, plus all individuals with no
malaria episodes but without parasites detectable by microscopy
and (2) only individuals with no malaria episodes but with
definitive exposure as indicated by parasites detectable by
microscopy during the follow up. The second analyses involving
control group (2) was to account for any possible confounding due
to heterogeneity in exposure. This was because, the group
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comprising individuals apparently protected but without detect-
able parasitaemia by microscopy may also include individuals who
did not have malaria due to lack of exposure to the parasite during
the follow up period. Additional sensitivity SNP association
analyses (logistic regression) were performed with a generalized
estimating equation (GEE) approach to correct all confidence
limits and p-values for the family structure in the data. Linkage
disequilibrium (LD) in the FCGR3B SNPs and visualisation of
pairwise r2 LD values were evaluated using Haploview v. 4.2 [54].
Association of FCGR3B haplotypes with clinical malaria was
analysed using the Hapassoc package v. 1.2–4 in R [55]. The
pooling tolerance was set to 0.03 in order to restrict the association
analysis to haplotypes whose frequency exceeded 3% in the
population. The haplotype with the highest frequency was used as
the reference. Comparison to the other haplotypes was performed
using nested logistic regression adjusting for age group, gender, sickle
cell status, blood group, use of bed net and ethnic group. Except for the
LD and pairwise r2 visualization, all statistical analyses were performed
using R v. 2.13.2 (http://www.R-project.org). DnaSP v. 5.10 (http://
www.ub.edu/dnasp/) was used to estimate Tajima’s D for exon 3 of
FCGR3B the Ghanaian and Danish populations. The window length
for the Tajima’s sliding window analysis was 50 with step size of 10
nucleotides. Genotyping data for rs5030738 was retrieved from the
1000 Genomes Project database (http://browser.1000genomes.org/
Homo_sapiens/Variation/Population?db=core;g=ENSG00000162
747;r=1:161592986-161601753;t= ENST00000531221;v = rs50307
38;vdb=variation;vf=8673417); for the African (AFR); Ad Mixed
American (AMR) and European (EUR) super populations and allele
frequencies compared among all 5 populations. Pairwise FST distances
were calculated for all 5 populations using the POPTREE2 software
[56].
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